TY - JOUR T1 - Overlapping Substrate and Inhibitor Specificity of Human and Murine ABCG2 JF - Drug Metabolism and Disposition JO - Drug Metab Dispos DO - 10.1124/dmd.113.053140 SP - dmd.113.053140 AU - Joshua Bakhsheshian AU - Matthew D. Hall AU - Robert W. Robey AU - Michelle A. Herrmann AU - Jin-Qiu Chen AU - Susan E. Bates AU - Michael M. Gottesman Y1 - 2013/01/01 UR - http://dmd.aspetjournals.org/content/early/2013/07/18/dmd.113.053140.abstract N2 - ABCG2 (also known as breast cancer resistance protein; BCRP) is an ATP-binding cassette (ABC) transporter localized to the plasma membrane where it mediates the efflux of xenobiotics, including potential therapeutics. Studies investigating Abcg2 function at the blood-brain-barrier in mouse models are often compared to human ABCG2 function. It is critical to understand the nature of species differences between mouse and human ABCG2, since extrapolations are made from murine data to humans. Two independent drug-selected cell line pairs expressing human or mouse ABCG2 were compared for efflux of fluorescent substrates using flow cytometry. To this end, we developed and characterized a new mouse Abcg2-expressing subline that demonstrated efflux of known fluorescent ABCG2 substrates and increased resistance to mitoxantrone, which is reduced in the presence of the ABCG2 inhibitor Ko143. Our results indicate that the substrate specificity of human and mouse ABCG2 is very similar. We identified a new human and mouse ABCG2 substrate, a porphyrin analog, purpurin-18 (Pp-18), which is not a substrate for P-gp or MRP1. The ability of inhibitors to block efflux activity of ABCG2 was assessed using Pp-18. Inhibitors also demonstrated similar effects on human and mouse ABCG2. Chrysin, benzoflavone, and cyclosporin A inhibited Pp-18 efflux in both human and mouse ABCG2. The similarity of the substrate and inhibitor specificity of human and mouse ABCG2 supports interpretation of mouse models in understanding the clinical, pharmacological and physiological roles of ABCG2. ER -